Filing search / Incannex Healthcare Limited / "Litigation"

PRE 14A

IXHL Incannex Healthcare Limited

31 Oct 24

Preliminary proxy

4:10pm

their independence. The audit committee also considered the status of pending litigation, taxation matters and other areas of oversight relating

8-K

EX-99.1

IXHL Incannex Healthcare Limited

24 Oct 24

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

7:30am

Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: Incannex’s … transactions; the impact of any infringement actions or other litigation brought against Incannex; the success of Incannex’s development efforts

8-K

EX-10.2

IXHL Incannex Healthcare Limited

21 Oct 24

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

4:35pm

, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable … securing this Debenture, including, without limitation, in connection with any litigation, mediation, bankruptcy or administrative proceeding

8-K

EX-10.1

IXHL Incannex Healthcare Limited

15 Oct 24

Entry into a Material Definitive Agreement

3:54pm

it is aware) litigation, arbitration or action in connection with or against it or its Secured Property or assets which would have, or which might … or applicable law; Facility Agreement – Incannex any enquiry, investigation, subpoena (or similar order) or litigation with respect to an Obligor

8-K

EX-99.1

IXHL Incannex Healthcare Limited

30 Sep 24

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

4:01pm

of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release … to raise capital to fund continuing operations and to complete capital raising transactions; the impact of any infringement actions or other litigation

10-K

EX-19.1

ahqrudt2jddp4

30 Sep 24

Annual report

7:30am

10-K

jhyhkob mfl60l

30 Sep 24

Annual report

7:30am

8-K

EX-99.1

ei6a4afi cm4omk6h

10 Sep 24

Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors

8:00am

8-K

EX-10.1

vg5hm7n

10 Sep 24

Entry into a Material Definitive Agreement

7:30am

8-K

EX-10.2

51tdbp 5x3

10 Sep 24

Entry into a Material Definitive Agreement

7:30am

8-K

EX-99.1

epgbpgsl pm8ms

5 Aug 24

FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed

8:15am

8-K

EX-99.1

i4u7z4wbu72ja

30 Jul 24

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X

9:00am

S-1/A

934gudy

17 Jul 24

IPO registration (amended)

8:47am

S-1/A

EX-10.9

gkirv

17 Jul 24

IPO registration (amended)

8:47am

S-1

c4pfdk4

3 Jul 24

IPO registration

6:29am

8-K

EX-99.1

3ljfg5c

30 May 24

Other Events

8:30am

8-K

EX-99.1

dox9idcgk7a

7 May 24

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder

8:30am

8-K

EX-99.1

3huuqr6p

16 Apr 24

Incannex Healthcare Inc. Quarterly Update, Q1 2024

9:30am

8-K

EX-99.1

w88 ij1rewmo

28 Feb 24

Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

7:42am